U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Assasi N, Ryce A. Icatibant for Patients with Type III Hereditary Angioedema: An Updated Review of Clinical Effectiveness and Harms [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Mar 9.

Cover of Icatibant for Patients with Type III Hereditary Angioedema: An Updated Review of Clinical Effectiveness and Harms

Icatibant for Patients with Type III Hereditary Angioedema: An Updated Review of Clinical Effectiveness and Harms [Internet].

Show details

References

1.
Betschel S, Badiou J, Binkley K, Hebert J, Kanani A, Keith P, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol [Internet]. 2014 [cited 2017 Feb 24];10(1):50. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC4210625
2.
Lumry WR. Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care. 2013 Jun;19(7 Suppl):s103–s110. [PubMed: 23844782]
3.
Banerji A, Busse P, Christiansen SC, Li H, Lumry W, Davis-Lorton M, et al. Current state of hereditary angioedema management: a patient survey. Allergy Asthma Proc [Internet]. 2015 May [cited 2017 Feb 21];36(3):213–7. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC4405601 [PMC free article: PMC4405601] [PubMed: 25976438]
4.
Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol [Internet]. 2005 Mar [cited 2017 Mar 2];139(3):379–94. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC1809312 [PMC free article: PMC1809312] [PubMed: 15730382]
5.
Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012 Sep;130(3):692–7. [PubMed: 22841766]
6.
Craig TJ, Bernstein JA, Farkas H, Bouillet L, Boccon-Gibod I. Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting [Internet]. Int Arch Allergy Immunol. 2014 [cited 2017 Feb 21];165(2):119–27. Available from: https://www​.karger.com​/Article/Pdf/368404 [PubMed: 25401373]
7.
Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (icatibant). J Allergy Clin Immunol. 2007 Jun;119(6):1497–503. [PubMed: 17418383]
8.
Wu E. Hereditary angioedema with normal C1 inhibitor. In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; 2016 Mar 31 [cited 2017 Feb 24]. Available from: www​.uptodate.com Subscription required.
9.
Cicardi M, Bergamaschini L, Cugno M, Beretta A, Zingale LC, Colombo M, et al. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology. 1998 Aug;199(2):366–76. [PubMed: 9777420]
10.
Bork K, Barnstedt SE, Koch P, Traupe H Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000 Jul 15;356(9225):213–7. [PubMed: 10963200]
11.
Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011 Dec;107(6):529–37. [PubMed: 22123383]
12.
Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med [Internet]. 2010 Aug 5 [cited 2017 Mar 8];363(6):532–41. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC4662377 [PMC free article: PMC4662377] [PubMed: 20818888]
13.
Bhardwaj N, Craig TJ Treatment of hereditary angioedema: a review (CME). Transfusion. 2014 Nov;54(11):2989–96. [PubMed: 24735226]
14.
Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy [Internet]. 2017 Feb [cited 2017 Mar 8];72(2):300–13. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC5248622 [PMC free article: PMC5248622] [PubMed: 27503784]
15.
Icatibant for patients with type III hereditary angioedema: a review of clinical effectiveness and harms [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2014 Feb 6. [cited 2017 Mar 9]. (CADTH rapid response report: summary with critical appraisal). Available from: https://www​.cadth.ca​/sites/default/files​/pdf/htis/apr-2014/RC0518%20Icatibant​.pdf [PubMed: 25654149]
16.
Methodology checklist 3: cohort studies [Internet]. Edinburgh, United Kingdom: Scottish Intercollegiate Guidelines Network; 2012 Nov 20. [cited 2017 Mar 9]. Available from: http://www​.sign.ac.uk​/methodology/checklists​/20121210_Checklist​_for_cohort_studies.rtf
17.
Moga C, Guo B, Schopflocher D, Harstall C. Development of a quality appraisal tool for case series studies using a modified Delphi technique [Internet]. Edmonton (AB): Institute of Health Economics; 2012 Mar. [cited 2017 Mar 9]. (IHE methodology paper). Available from: http://www​.ihe.ca/download​/development_of​_a_quality_appraisal​_tool_for_case_series​_studies_using_a_modified​_delphi_technique.pdf
18.
Deroux A, Boccon-Gibod I, Fain O, Pralong P, Ollivier Y, Pagnier A, et al. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema. Clin Exp Immunol. 2016 Sep;185(3):332–7. [PMC free article: PMC4991515] [PubMed: 27271546]
19.
Javaud N, Gompel A, Bouillet L, Boccon-Gibod I, Cantin D, Smaiti N, et al. Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Ann Allergy Asthma Immunol. 2015 Jun;114(6):499–503. [PubMed: 25935434]
20.
Piñero-Saavedra M, González-Quevedo T, Saenz de San Pedro B, Alcaraz C, Bobadilla-González P, Fernández-Vieira L, et al. Hereditary angioedema with F12 mutation: clinical features and enzyme polymorphisms in 9 Southwestern Spanish families. Ann Allergy Asthma Immunol. 2016 Nov;117(5):520–6. [PubMed: 27788882]
21.
Bouillet L, Boccon-Gibod I, Launay D, Gompel A, Kanny G. Hereditary angioedema with normal C1 inhibitor in a French cohort: clinical characteristics and response to treatment with icatibant. Immun Inflamm Dis. 2017 Mar;5(1):29–36. [PMC free article: PMC5322159] [PubMed: 28250922]
22.
Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015 May;277(5):585–93. [PubMed: 25196353]
23.
Firinu D, Bafunno V, Vecchione G, Barca MP, Manconi PE, Santacroce R, et al. Characterization of patients with angioedema without wheals: the importance of F12 gene screening. Clin Immunol. 2015 Apr;157(2):239–48. [PubMed: 25744496]
24.
Bork K, Wulff K, Hardt J. Treatment with icatibant in hereditary angioedema with normal C1 inhibitor without F12 gene mutations. Allergy. 2017;70(Suppl S101):472–73.
25.
Kuhlen J, Mehra A, Conroy M. Hereditary angioedema with normal C1 inhibitor response to progesterone therapy: a case report and review of the literature. J Angioedema [Internet]. 2014 [cited 2017 Feb 24];1(3):13–7. Available from: http://www​.journalofangioedema​.com/pub/IssuePDFs/Kuhlen.pdf
26.
Garro LS, Porter M, Komaroff F, Adachi C. Therapeutic trial in hereditary angioedema type III: icatibant [abstract]. World Allergy Organ J [Internet]. 2015 [cited 2017 Feb 24];8(Suppl 1):A220. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC4407049/pdf/1939-4551-8-S1-A220.pdf
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK470520
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (726K)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...